Mumbai: Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing tablets of Clopidogrel bisulfate and a tentative approval for the tablets Clopidogrel bisulfate, which are used to help reduce risk of heart attack or stroke. Clopidogrel is the generic name for brand Plavix, marketed in the United States by Bristol-Myers Squibb. Wockhardt is launching the product immediately, a company statement said here. According to IMS Health, the total market for this product in the US was over USD 6,500 million. Prevalence of atherosclerotic diseases is rapidly growing the world over. But by inhibiting the clotting within blood vessels, it reduces risk of heart attacks and strokes and is one of the most used pharmaceutical products in the world.
Alcohol leads to stunted growth in babies: Study
Continuous oral contraceptives offer relief from menstrual pain